Management of prehospital antiplatelet and anticoagulant therapy in traumatic head injury: A review

Journal of Trauma - Injury, Infection and Critical Care

Volumn 66, Issue 3, 2009, Pages 942-950

  McMillian, Wesley D ^a,b   Rogers, Frederick B ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Aspirin; Clopidogrel; Intracranial hemorrhage; Trauma; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DALTEPARIN; DICLOFENAC; DIFLUNISAL; ENOXAPARIN; ETODOLAC; FENOPROFEN; FONDAPARINUX; HEPARIN; HEPARINOID; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LOW MOLECULAR WEIGHT HEPARIN; MECLOFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; TICLOPIDINE; TINZAPARIN; UNINDEXED DRUG; WARFARIN; ARGIPRESSIN[1 DEAMINO]; BLOOD CLOTTING FACTOR 7A; HEMOSTATIC AGENT; PHYTOMENADIONE; PROTAMINE; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG INDICATION; EMBOLISM; EMERGENCY CARE; EMERGENCY WARD; GLASGOW COMA SCALE; HEAD INJURY; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INJURY SEVERITY; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUNG EMBOLISM; MORBIDITY; MORTALITY; OUTPATIENT CARE; PRIORITY JOURNAL; REVIEW; SUBDURAL HEMATOMA; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; TREATMENT OUTCOME; AGED; BRAIN INJURY; CHEMICALLY INDUCED DISORDER; EMERGENCY HEALTH SERVICE; EPIDURAL HEMATOMA; INTENSIVE CARE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PLASMA; RISK FACTOR;

AGED; ANTICOAGULANTS; BRAIN INJURIES; CEREBRAL HEMORRHAGE, TRAUMATIC; COMBINED MODALITY THERAPY; CRITICAL CARE; DEAMINO ARGININE VASOPRESSIN; EMERGENCY MEDICAL SERVICES; FACTOR VIIA; HEMATOMA, EPIDURAL, CRANIAL; HEMATOMA, SUBDURAL; HEMOSTATICS; HOSPITAL MORTALITY; HUMANS; MIDDLE AGED; PLASMA; PLATELET AGGREGATION INHIBITORS; PLATELET TRANSFUSION; PROTAMINES; RECOMBINANT PROTEINS; RISK FACTORS; VITAMIN K 1;

EID: 68149183033     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e3181978e7b     Document Type: Review

References (40)

1. Cohen DB, Rinker C, Wilberger JE. Traumatic brain injury in anticoagulated patients. J Trauma. 2006;60:553-557.
2. Ferrera PC, Bartfield JM. Outcomes of anticoagulated trauma patients. Am J Emerg Med. 1999;17:154-156.
3. Franko J, Kish KJ, O'Connell BG, et al. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. J Trauma. 2006;61:107-110.
4. Mattle H, Kohler S, Huber P, et al. Anticoagulation-related intracranial extracerebral haemorrhage. J Neurol Neurosurg Psychiatry. 1989;52:829-837.
5. Kalgutkar AS, Crews BC, Rowlinson SW, et al. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science. 1998;280:1268-1270.
6. Chang H, Jahng Y. Cyclooxygenase-2 inhibitors as anti-inflammatory agents. Korean J Med Chem. 1998;8:48-79.
7. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120.
8. McEvoy GK. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2005.
9. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
10. Product Information: Plavix Oral Tablets. Bristol-Myers Squibb/Sanofi Aventis, Bridgewater, NJ; October 2007.
11. Mills DC, Puri R, Hu CJ, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb. 1992;12:430-436.
12. Rozzelle CJ, Wofford JL, Branch CL. Predictors of hospital mortality in older patients with subdural hematoma. J Am Geriatr Soc. 1995;43:240-244.
13. Mina AA, Knipfer JF, Park DY, et al. Intracranial complications of preinjury anticoagulation in trauma patients with head injury. J Trauma. 2002;53:668-672.
14. Spektor S, Agus S, Merkin V, et al. Low-dose aspirin prophylaxis and risk of intracranial hemorrhage in patients older than 60 years of age with mild or moderate head injury: a prospective study. J Neurosurg. 2003;99:661-665.
15. Ohm C, Mina A, Howells G, et al. Effects of antiplatelet agents on outcomes for elderly patients with traumatic intracranial hemorrhage. J Trauma. 2005;58:518-522.
16. Jones K, Sharp C, Mangram AJ, et al. The effects of preinjury clopidogrel use on older trauma patients with head injuries. Am J Surg. 2006;192:743-745.
17. Turpie AG. Pharmacology of the low-molecular-weight heparins. Am Heart J. 1998;135:S329-S335.
18. Haines ST, Bussey HI. Thrombosis and the pharmacology of antithrombotic agents. Ann Pharmacother. 1995;29:892-905.
19. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001;344:619-625.
20. Karni A, Holtzman R, Bass T, et al. Traumatic head injury in the anticoagulated elderly patient: a lethal combination. Am Surg. 2001;67:1098-1100.
21. Lavoie A, Ratte S, Clas D, et al. Preinjury warfarin use among elderly patients with closed head injuries in a trauma center. J Trauma. 2004;56:802-807.
22. Pieracci FM, Eachempati SR, Shou J, et al. Degree of anticoagulation, but not warfarin use itself, predicts adverse outcomes after traumatic brain injury in elderly trauma patients. J Trauma. 2007;63:525-530.
23. Wojcik R, Cipolle MD, Seislove E, et al. Preinjury warfarin does not impact outcome in trauma patients. J Trauma. 2001;51:1147-1151.
24. Altman R, Scazziota A, Delh M, et al. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost. 2006;4:2022-2027.
25. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost. 2003;1:682-689.
26. Kjalke M, Oliver JA, Monroe DM, et al. The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. Thromb Haemost. 1997;78:1202-1208.
27. Powner DJ, Hartwell EA, Hoots WK. Counteracting the effects of anticoagulants and antiplatelet agents during neurosurgical emergencies. Neurosurgery. 2005;57:823-831.
28. Vilahur G, Choi BG, Zafar MU, et al. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost. 2007;5:82-90.
29. Ranucci M, Nano G, Pazzaglia A, et al. Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy. J Cardiothorac Vasc Anesth. 2007;21:851-854.
30. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):204S-233S.
31. Norda R, Tynell E, Akerblom O. Cumulative risks of early fresh frozen plasma, cryoprecipitate and platelet transfusion in Europe. J Trauma. 2006;60(6 Suppl):S41-S45.
32. Ivascu FA, Janczyk RJ, Junn FS, et al. Treatment of trauma patients with intracranial hemorrhage on preinjury warfarin. J Trauma. 2006;61:318-321.
33. Ivascu FA, Howells GA, Junn FS, et al. Rapid warfarin reversal in anticoagulated patients with traumatic intracranial hemorrhage reduces hemorrhage progression and mortality. J Trauma. 2005;59:1131-1137.
34. Novoseven (recombinant activated factor VII) Product Information. Bagsvaerd, Denmark; 2007.
35. Narayan RK, Maas AI, Marshall LF, et al. Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial. Neurosurgery. 2008;62:776-786.
36. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785.
37. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127-2137.
38. Dutton RP, McCunn M, Hyder M, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma. 2004;57:709-718.
39. Shander AGL, Ratko T, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (Novoseven) therapy. Pharm Ther. 2005;30:644-658.
40. Dager WE, King JH, Regalia RC, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy. 2006;26:1091-1098.